IASLC TTLC 2022 | Novel treatment strategies for BRAF V600E-mutant NSCLC

Dabrafenib plus trametinib have demonstrated promising efficacy in patients with BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC) and alternative doublet combinations based on existing melanoma therapies are current under investigation. Bruce Johnson, MD, Dana-Farber Cancer Institute, Boston, MA, describes the trial design of the ongoing Phase II PHAROS trial (NCT03915951), which aims to investigate encorafenib and binimetinib, a BRAF and MEK inhibitor respectively, in patients with BRAF V600E-mutant NSCLC. This interview took place at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC 2022).